These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 21756282

  • 1. Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.
    Noon AP, Polański R, El-Fert AY, Kalirai H, Shawki H, Campbell F, Dodson A, Eccles RM, Lloyd BH, Sibson DR, Coupland SE, Lake SL, Parsons K, Vlatković N, Boyd MT.
    BJU Int; 2012 Apr; 109(8):1250-7. PubMed ID: 21756282
    [Abstract] [Full Text] [Related]

  • 2. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y, Dahiya R.
    Clin Cancer Res; 2007 Jul 15; 13(14):4123-9. PubMed ID: 17634539
    [Abstract] [Full Text] [Related]

  • 3. P53 and MDM2 Over-expression and Five-year Survival of Kidney Cancer Patients Undergoing Radical Nephrectomy--Iranian Experience.
    Abolhasani M, Salarinejad S, Asgari M.
    Asian Pac J Cancer Prev; 2015 Jul 15; 16(12):5043-7. PubMed ID: 26163638
    [Abstract] [Full Text] [Related]

  • 4. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
    Zigeuner R, Ratschek M, Rehak P, Schips L, Langner C.
    Urology; 2004 Apr 15; 63(4):651-5. PubMed ID: 15072872
    [Abstract] [Full Text] [Related]

  • 5. Activation of PI3K is associated with reduced survival in renal cell carcinoma.
    Merseburger AS, Hennenlotter J, Kuehs U, Simon P, Kruck S, Koch E, Stenzl A, Kuczyk MA.
    Urol Int; 2008 Apr 15; 80(4):372-7. PubMed ID: 18587247
    [Abstract] [Full Text] [Related]

  • 6. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma.
    Petraki CD, Gregorakis AK, Vaslamatzis MM, Papanastasiou PA, Yousef GM, Levesque MA, Diamandis EP.
    Tumour Biol; 2006 Apr 15; 27(1):1-7. PubMed ID: 16340244
    [Abstract] [Full Text] [Related]

  • 7. The polymorphisms of P53 codon 72 and MDM2 SNP309 and renal cell carcinoma risk in a low arsenic exposure area.
    Huang CY, Su CT, Chu JS, Huang SP, Pu YS, Yang HY, Chung CJ, Wu CC, Hsueh YM.
    Toxicol Appl Pharmacol; 2011 Dec 15; 257(3):349-55. PubMed ID: 21982800
    [Abstract] [Full Text] [Related]

  • 8. IMPORTANCE OF APOPTOSIS MARKERS (MDM2, BCL-2 AND Bax) IN CONVENTIONAL RENAL CELL CARCINOMA.
    Saker Z, Tsintsadze O, Jiqia I, Managadze L, Chkhotua A.
    Georgian Med News; 2015 Dec 15; (249):27-33. PubMed ID: 26719546
    [Abstract] [Full Text] [Related]

  • 9. The clinicopathological significance and relationship of Gli1, MDM2 and p53 expression in resectable pancreatic cancer.
    Sheng W, Dong M, Zhou J, Li X, Liu Q, Dong Q, Li F.
    Histopathology; 2014 Mar 15; 64(4):523-35. PubMed ID: 24289472
    [Abstract] [Full Text] [Related]

  • 10. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters.
    Haitel A, Wiener HG, Baethge U, Marberger M, Susani M.
    Clin Cancer Res; 2000 May 15; 6(5):1840-4. PubMed ID: 10815906
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?
    Noon AP, Vlatković N, Polański R, Maguire M, Shawki H, Parsons K, Boyd MT.
    Cancer; 2010 Feb 15; 116(4):780-90. PubMed ID: 20052733
    [Abstract] [Full Text] [Related]

  • 14. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
    Nishikawa M, Miyake H, Harada K, Fujisawa M.
    Urol Oncol; 2014 Jan 15; 32(1):49.e15-21. PubMed ID: 24239474
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma.
    Shvarts O, Seligson D, Lam J, Shi T, Horvath S, Figlin R, Belldegrun A, Pantuck AJ.
    J Urol; 2005 Mar 15; 173(3):725-8. PubMed ID: 15711252
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.